Literature DB >> 32418497

Clinical Applicability of Monitoring Antihypertensive Drug Levels in Blood.

Laura E J Peeters1,2, Lida Feyz3, Eric Boersma3, Joost Daemen3, Teun van Gelder1,2, Birgit C P Koch1, Jorie Versmissen2.   

Abstract

Dried blood spot (DBS) analysis is a novel analytical method for therapeutic drug monitoring to identify nonadherence to antihypertensive drugs. This study was conducted to evaluate the clinical applicability of measuring drug concentrations of 8 antihypertensive drugs, using DBS and venipuncture. Furthermore, this study aimed to provide more insight into the between-patient variability in drug concentrations. False-negative values from DBS compared with a venipuncture were determined to assess drug adherence. A generalized estimating equation was used to estimate the model parameters, including sex, dose, age, weight, and the time interval, between drug intake and sampling, on the Cplasma (drug concentration in plasma). No false-negative values were found when measuring nonadherence using DBS compared with venipuncture. A high variability in Cplasma between patients was observed, especially at peak concentrations with a fold change reaching from 2.3 to 35.2. The time of intake was significantly related to the height of the Cplasma in 7 of the 8 measured drugs with a P<0.05, but the influence of dose, weight, age, and sex on drug levels differed largely between the measured drugs. DBS is a reliable and convenient method to assess nonadherence to antihypertensive drugs in clinical practice. The Cplasma of the 8 antihypertensive drugs in this study show a large interindividual difference, and therefore, low plasma concentrations do not necessarily mean nonadherence. Nonadherence can only be confirmed if drug levels are undetectable, that is, values below the lower limit of detection.

Entities:  

Keywords:  antihypertensive drugs; drug monitoring; hypertension; limit of detection; phlebotomy

Mesh:

Substances:

Year:  2020        PMID: 32418497     DOI: 10.1161/HYPERTENSIONAHA.120.15038

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

Review 1.  The position of renal denervation in treatment of hypertension: an expert consensus statement.

Authors:  V J M Zeijen; A A Kroon; B H van den Born; P J Blankestijn; S C A Meijvis; A Nap; E Lipsic; A Elvan; J Versmissen; R J van Geuns; M Voskuil; P A L Tonino; W Spiering; J Deinum; J Daemen
Journal:  Neth Heart J       Date:  2022-08-24       Impact factor: 2.854

2.  Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations.

Authors:  Laura E J Peeters; Soma Bahmany; Tim Dekker; Aya Aliawi; Bart van Domburg; Jorie Versmissen; Birgit C P Koch
Journal:  Ther Drug Monit       Date:  2022-04-05       Impact factor: 3.118

3.  Introducing the importance and difficulties of a three-step approach to improve nonadherence to antihypertensive drugs: a case series.

Authors:  Laura E J Peeters; Jeroen B van der Net; Kathy Schoenmakers-Buis; Irene M van der Meer; Emma K Massey; Liset van Dijk; Teun van Gelder; Birgit C P Koch; Jorie Versmissen
Journal:  J Hypertens       Date:  2022-01-01       Impact factor: 4.844

Review 4.  Plasma Trough Concentrations of Antihypertensive Drugs for the Assessment of Treatment Adherence: A Meta-Analysis.

Authors:  Eline H Groenland; Monique E A M van Kleef; Michiel L Bots; Frank L J Visseren; Kim C M van der Elst; Wilko Spiering
Journal:  Hypertension       Date:  2020-11-30       Impact factor: 10.190

5.  Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence.

Authors:  Laura E J Peeters; Leonardien K Tjong; Wim J R Rietdijk; Teun van Gelder; Birgit C P Koch; Jorie Versmissen
Journal:  Biomedicines       Date:  2022-01-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.